Dr. Nworah Ayogu’s AI vision is a 40 trillion indictment
By Maya Ellison · Reporting from Detroit ·
As Thrive Capital celebrates the "hero use case" of OpenAI, automating care and pricing cures at millions per patient will never fix a system that spent 40 trillion for no change.
On the podcast Sourcery, Dr. Nworah Ayogu of Thrive Capital made a haunting claim. OpenAI is now effectively the largest healthcare provider in America. Every week, 300 million people ask ChatGPT for medical advice. To Ayogu, this is a "hero use case." To those in zip codes where the pharmacy is a liquor store, it sounds like a surrender. Trusting a chatbot isn't a tech triumph. It is a symptom of a system priced out of human reach.
The forty trillion dollar ghost
Ayogu, a Harvard-trained physician and venture capitalist, laid out a record of failure. He noted that the United States spent 40 trillion on healthcare over the last decade. National life expectancy did not move "an inch." He rightly called this an "indictment" of the system. Yet, his solutions only double down on the interests that created the stagnation. He pitched AI-driven drug discovery and "N-of-1" customized medicine to host Molly.
He pointed to "baby K.J.," a child saved by a custom gene therapy. It cost a million and a half dollars to develop and deliver. While a miracle for that family, Ayogu admitted the system must grapple with "what is the price of a life." For the venture capital class, that price is a market opportunity. For the rest of us, it’s a barrier. We celebrate this cure while life expectancy in West Virginia sits at 72. We are building a world where science is a gated community.
The 10x nurse and the automation trap
Perhaps the most revealing moment came when Ayogu pivoted to labor. He argued that America needs a "10x nurse" more than a "10x engineer." On its face, it sounds like a tribute to essential workers. But in the language of venture capital, a "10x" worker is rarely one who gets a raise. It is one forced to be 10x more productive through automation.
Ayogu praised companies like Cadence. It uses "AI agents" to monitor patients at home. These agents intervene the moment a blood pressure reading spikes. They catch patients before they go to "bingo" or "Trader Joe's." He boasted that these AI recommendations have a 98% concordance rate with doctors. This is the "bilingual" future Thrive is funding. It is a world where the "back office" is stripped of human judgment. One professional supervises a fleet of algorithms while the board pockets the difference.
Enclosing the human substrate
This drive for efficiency extends into the human body itself. Ayogu argued that Neuralink is a "more interesting" company than SpaceX because the brain is a "vaster" frontier than space. He described the "biblical" proportions of these technologies—making the lame walk and the mute speak. But he also spoke of "vertical integration through all parts of our supply chain," including pathology and neurosurgery.
Treating the brain as a "vertical" is the ultimate enclosure of the commons. Ayogu’s vision is one of "trillion-dollar healthcare companies." They own the hardware in our ears and the chips in our heads. He sees a "shoppable model" for care delivery. My father’s UAW dental plan didn't treat health like a line of code. It treated it as a right earned through labor.
We do not need a 10x nurse. We need nurses who have time to hold a patient’s hand. We do not need a chatbot to be our primary care physician. We have 40 trillion to spend. We should spend it on the people who do the work. The "frontier of science" is worthless if it requires a million and a half dollars toll booth.